18 and older, any sex, with Obesity or Anxiety Sensitivity. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Anxiety Sensitivity Index-3Primary· Baseline,1-week, 2-week and 1-month follow-up
The Anxiety Sensitivity Index-3 is an 18-item measured that will be used to assess sensitivity to, and fear of, the potential negative consequences of anxiety-related symptoms and sensations. Items are rated on a 5-point Likert scale, ranging from 0 (Very Little) to 4 (Very Much). Scores will be calculated by summing all items (possible range = 0 -72), with lower scores indicating a better outcome.
Baseline
Group
Value
95% CI
Anxiety Sensitivity Training
43.44
± 12.27
Health Control
43.00
± 12.43
1-Week Follow-up
Group
Value
95% CI
Anxiety Sensitivity Training
40.17
± 14.03
Health Control
40.69
± 13.15
2-Week Follow-up
Group
Value
95% CI
Anxiety Sensitivity Training
38.00
± 15.13
Health Control
37.24
± 14.10
1-Month Follow-up
Group
Value
95% CI
Anxiety Sensitivity Training
37.74
± 16.29
Health Control
34.25
± 13.93
Dutch Eating Behavior QuestionnairePrimary· Baseline,1-week, 2-week and 1-month follow-up
The Dutch Eating Behavior Questionnaire will be used to assess emotional eating. Items are rated on a 5-point Likert scale ranging from 1 (never) to 5 (very often). For the current study, the emotional eating subscale (13 items) will be used as a measure of emotional eating. The 13 items of the subscale are summed and divided by 13 to create a mean score with a range from 1-5. Lower scores on this measure indicate better outcomes.
Baseline
Group
Value
95% CI
Anxiety Sensitivity Training
3.58
± 0.91
Health Control
3.68
± 0.87
1-Week Follow-up
Group
Value
95% CI
Anxiety Sensitivity Training
3.54
± 1.03
Health Control
3.59
± 0.92
2-Week Follow-up
Group
Value
95% CI
Anxiety Sensitivity Training
3.31
± 1.08
Health Control
3.52
± 0.94
1-Month Follow-up
Group
Value
95% CI
Anxiety Sensitivity Training
3.21
± 1.15
Health Control
3.35
± 0.98
Eating Expectancy InventoryPrimary· Baseline,1-week, 2-week and 1-month follow-up
The Eating Expectancy Inventory will be used to measure cognitive expectancies of eating. The Eating Expectancy Inventory subscale facet: eating helps manage negative affect will be used in the current study. Respondents will be asked to rate on a 7-point Likert scale the degree to which they 1 (completely disagree) to 7 (completely agree) to each item. Responses are summed for each subscale. Lower scores on the 18-item eating helps manage negative affect subscale (possible range = 18 - 126) indicate better outcomes.
Baseline
Group
Value
95% CI
Anxiety Sensitivity Training
88.17
± 22.11
Health Control
90.06
± 20.69
1-Week Follow-up
Group
Value
95% CI
Anxiety Sensitivity Training
85.98
± 25.89
Health Control
89.03
± 23.08
2-Week Follow-up
Group
Value
95% CI
Anxiety Sensitivity Training
82.19
± 26.18
Health Control
88.30
± 23.15
1-Month Follow-up
Group
Value
95% CI
Anxiety Sensitivity Training
80.74
± 28.71
Health Control
87.51
± 22.59
Exercise Self-EfficacyPrimary· Baseline,1-week, 2-week and 1-month follow-up
Exercise self-efficacy will be assessed with a 5-item self-report assessment of one's confidence about their ability to engage in physical activity. Items are rated on a 9-point Likert-type scale that ranges from 0 (not at all confident) to 8 (extremely confident). A total score will be created by summing the 5-items with higher scores indicating a better outcome (possible range 0 - 40).
Baseline
Group
Value
95% CI
Anxiety Sensitivity Training
14.11
± 9.31
Health Control
16.59
± 8.13
1-Week Follow-up
Group
Value
95% CI
Anxiety Sensitivity Training
16.37
± 9.77
Health Control
18.06
± 8.11
2-Week Follow-up
Group
Value
95% CI
Anxiety Sensitivity Training
15.52
± 9.14
Health Control
17.54
± 8.48
1-Month Follow-up
Group
Value
95% CI
Anxiety Sensitivity Training
16.32
± 9.51
Health Control
17.20
± 8.20
Sponsor's own description
The proposed study will design and evaluate a computerized-delivered single-session anxiety sensitivity reduction program (i.e., Anxiety Sensitivity Training; AST). The AST will be designed to achieve three primary aims: (1) provide psycho-educational information on AS and its consequences, (2) present psycho-educational information on the relationship between AS and obesity-related health behavior correlates, and (3) offer concrete, evidence-based strategies to facilitate motivation to change their obesity-related lifestyle behaviors.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT07403604 — Effect of Insulin Lowering on Lipogenesis
· Phase 1
· recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee
· Phase 3
· recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
· recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart
· Phase 3
· recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl
· Phase 1
· recruiting
Other University of Houston trials
Trials by the same sponsor.
NCT07024992 — Enhancing Smoking Cessation for African American People Everywhere
· Phase 2
· not yet recruiting
NCT07025772 — Shaping Habitual Impulses For a Tobacco-free Style
· NA
· recruiting
NCT07007195 — Smart Olfaction App to Reduce Relapse
· EARLY_PHASE1
· not yet recruiting
NCT06918821 — Reducing Obesity Through Play Among Toddlers: Tiny Steps to Health (TSHS) Study
· NA
· recruiting
NCT07227220 — Summer Youth Employment Programs for Health Promotion
· EARLY_PHASE1
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Houston
Last refreshed: 26 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03917901.